Activity and interactions of liposomal antibiotics in presence of polyanions and sputum of patients with cystic fibrosis
about
Novel formulations for antimicrobial peptidesInhalable Antimicrobials for Treatment of Bacterial Biofilm-Associated Sinusitis in Cystic Fibrosis Patients: Challenges and Drug Delivery Approaches.Bacteriophages and phage-derived proteins--application approachesPulmonary surfactant preserves viability of alveolar type II cells exposed to polymyxin B in vitroChallenges and advances in the development of inhalable drug formulations for cystic fibrosis lung disease.Inhaled antibiotics for gram-negative respiratory infections.Liposomal antibiotics for the treatment of infectious diseases.Liposomal antibiotic formulations for targeting the lungs in the treatment of Pseudomonas aeruginosa.Antimicrobial properties of liposomal azithromycin for Pseudomonas infections in cystic fibrosis patients.Efficacy and safety of liposomal clarithromycin and its effect on Pseudomonas aeruginosa virulence factors.The role of bacterial biofilms in chronic infections.Transport of nanoparticles in cystic fibrosis sputum and bacterial biofilms by single-particle tracking microscopy.Attenuation of Pseudomonas aeruginosa virulence factors and biofilms by co-encapsulation of bismuth-ethanedithiol with tobramycin in liposomes.Enhancement of lung gene delivery after aerosol: a new strategy using non-viral complexes with antibacterial properties.Targeting microbial biofilms: current and prospective therapeutic strategies.Targeting polyelectrolyte networks in purulent body fluids to modulate bactericidal properties of some antibiotics.
P2860
Q26991771-A6B6B674-2626-4AED-A02A-2E8608772288Q28077482-164A7FF7-26FF-465B-BB8A-3F247FB25D52Q28082731-3DF0E8CC-80C9-4E9E-B99C-5E3B7B62E284Q34689439-5B00B377-903E-4FDD-A50E-49596C74FE4FQ37849777-246A6BA3-6C46-4FEA-9E51-9611E67A1B30Q37937558-DE162096-F6DE-4180-8517-9797A9EA3F08Q38124144-A3D13B30-2DB0-4DA1-B888-2B95AE9930A7Q38214155-E36C222E-8E1C-46EF-838A-83C84974ECEEQ38938501-C30FDF06-D89F-4301-8546-0480BEE82264Q39172960-891A39D5-0441-423D-A32F-1811A0CD15A0Q39426830-CD52C272-D418-408C-BA60-B0AB48157AA4Q39542270-B33062F4-1F2E-4B39-BECA-A3338C0F1D17Q43160311-8583E056-6C1E-43DE-AF12-76243C2A773FQ44832157-13F6FC34-D47B-435C-9DF9-6C6A5EE93EB6Q47637669-3B22468C-FBCD-41CA-A0F2-4B3F6DF2FB06Q49387443-2C61EF73-F2B2-43F3-9D51-E71EEE7A9FA1
P2860
Activity and interactions of liposomal antibiotics in presence of polyanions and sputum of patients with cystic fibrosis
description
2009 nî lūn-bûn
@nan
2009 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Activity and interactions of l ...... patients with cystic fibrosis
@ast
Activity and interactions of l ...... patients with cystic fibrosis
@en
Activity and interactions of l ...... patients with cystic fibrosis
@nl
type
label
Activity and interactions of l ...... patients with cystic fibrosis
@ast
Activity and interactions of l ...... patients with cystic fibrosis
@en
Activity and interactions of l ...... patients with cystic fibrosis
@nl
prefLabel
Activity and interactions of l ...... patients with cystic fibrosis
@ast
Activity and interactions of l ...... patients with cystic fibrosis
@en
Activity and interactions of l ...... patients with cystic fibrosis
@nl
P2093
P2860
P921
P3181
P1433
P1476
Activity and interactions of l ...... patients with cystic fibrosis
@en
P2093
Ali O Azghani
Misagh Alipour
Zacharias E Suntres
P2860
P3181
P356
10.1371/JOURNAL.PONE.0005724
P407
P577
2009-05-28T00:00:00Z